SLP vs VEEV
SLP: Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry. VEEV: Veeva is the dominant cloud software and data platform powering the global life sciences industry from drug development through commercialization, with AI-enhanced solutions and a 16% annual revenue growth trajectory.
Side-by-side fundamentals
| Metric | SLP | VEEV | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $18.25 | $184.55 | |
| Market cap as of 2026-07-23 | $368M | $29.8B | |
| P/E as of 2026-07-23 | 45.47 | 31.67 | VEEV lower |
| PEG as of 2026-07-23 | n/a | 1.77 | |
| Net margin as of 2026-07-23 | +9.9% | +28.4% | VEEV higher |
| Gross margin as of 2026-07-23 | +63.4% | +75.0% | VEEV higher |
| Operating margin as of 2026-07-23 | +14.0% | +28.8% | VEEV higher |
| ROE as of 2026-07-23 | +6.2% | +13.4% | VEEV higher |
| ROA as of 2026-07-23 | +5.7% | +11.0% | VEEV higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +2.1% | +16.3% | VEEV higher |
| Revenue CAGR (3y) SEC XBRL | +13.7% | +14.0% | VEEV higher |
| Dividend yield as of 2026-07-23 | +0.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 1.34 | 0.92 | |
| 1-year return as of 2026-07-22 close | +40.0% | -35.3% | SLP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.